Delaware Chapter of the American College of CardiologyOur purpose is to contribute to the prevention of cardiovascular diseases, to ensure optimal quality of care for individuals with such diseases, and to foster the highest professional ethical standards. Please let us know what information you want to see here. Feel free to contact us with your ideas, needs and comments. |
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- Transcatheter Aortic Valve Implantation: Durability and Management of Valve FailureTranscatheter aortic valve implantation (TAVI) has become a cornerstone therapy for patients with severe aortic stenosis across a wide spectrum of clinical presentations and surgical risk. Initially reserved for patients at prohibitive or high surgical risk, TAVI is now widely adopted in populations at intermediate and low risk...
- ACC Leadership Update: Reflections and Highlights From the March BOT Meeting at ACC.26I am truly honored to serve as the new president of the ACC. I am excited to work alongside all of you over the coming year as we advance the College’s strategic priorities and continue our shared Mission to transform cardiovascular care for all.
- ACC Practice Made Perfect: The Dyad Leadership Model - Foundations for SuccessIn this kickoff episode sponsored by the CV Management Section, we explore what truly makes a dyad partnership effective in cardiovascular care.
- Clinical Practice Algorithm For the Follow-Up of Unrepaired and Repaired Tetralogy of FallotTetralogy of Fallot (TOF) is the most common form of cyanotic congenital heart disease (CHD). Early management of this condition is typically dictated by the degree of pulmonary stenosis (PS) and resulting oxygen saturations.
- Addressing Modifiable Barriers May Improve Access to Quadruple GDMT For Veterans With HFrEFAddressing modifiable barriers such as medication copays may improve access to care and outcomes for patients with heart failure with reduced ejection fraction (HFrEF), according to a cohort study published April 1 in JAMA Cardiology, which identified significant gaps in the rate and timeliness of quadruple therapy for veterans who are newly diagnosed.



